Peptide Atlas · Peptide

ARA-290

ARA 290 (cibinetide) is a non-haematopoietic peptide designed from the structure of erythropoietin that interacts selectively with the innate repair receptor mediating tissue protection.

emerging

provisional
PubChem 91810664
2 citations
0 discussions
0 followers
Cibinetide
pHBSP (pyroglutamate Helix B Surface Peptide)

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

- emerging
  Claim: Randomized pilot in sarcoidosis-associated small fibre neuropathy (22 patients) standing
- resolved
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.
Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A
pmid 23168581
- emerging
  Claim: Phase 2: metabolic control and neuropathic symptoms improved in type 2 diabetes standing
- resolved
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A
pmid 25387363

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.